Market capitalization | $28.53m |
Enterprise Value | $20.31m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.71 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-28.03m |
Free Cash Flow (TTM) Free Cash Flow | $-22.04m |
Cash position | $15.64m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
3 Analysts have issued a Polypid Ltd forecast:
3 Analysts have issued a Polypid Ltd forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -26 -26 |
25%
25%
|
EBIT (Operating Income) EBIT | -28 -28 |
23%
23%
|
Net Profit | -29 -29 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Head office | Israel |
CEO | Dikla Akselbrad |
Employees | 59 |
Founded | 2008 |
Website | www.polypid.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.